Tuesday, May 3, 2022

After $600M sales hit from pandemic, Merck’s open to ‘all forms’ of M&A deals, incoming CEO says


With Merck’s sales dragging from the pandemic and the company becoming increasingly reliant on immuno-oncology superstar Keytruda, the pharma giant’s executive team unveiled a willingness to flex its M&A muscle.

“We are open to any opportunity to add a meaningful asset,” president and soon-to-be CEO Rob Davis said on a Thursday call with investors. “We are open to all forms of deals and we have the capital” for those deals, he added.

The comments came during Merck’s first-quarter earnings call, where the drug giant reported sales for the period of $12.08 billion. Cancer mainstays Keytruda and Lynparza held the line, alongside surgery drug Bridion and the drugmaker’s animal health business. Elsewhere, pandemic disruptions took their toll.

In all, Merck missed analysts’ sales estimates by around $500 million. Analysts had figured the company would generate around $12.6 billion. 

Merck estimated that the COVID-19 pandemic took a roughly $600 million bite out of its pharma revenue during the first three months of the year. The company now expects the pandemic to crimp 2021 sales by around 3%.

RELAED: FDA panel backs Merck’s Keytruda nod in 1L bladder cancer—but new limits could be coming

Merck’s vaccine business suffered a particularly tough period as the COVID-19 vaccine rollout reached a fever pitch in the U.S. Sales of Merck’s HPV shot Gardasil fell 16% to $917 million, while revenues for its polysaccharide pneumococcal vaccine Pneumovax 23 dropped 33% to $171 million.

Those products could perform better in the back half of the year, once a majority of people in the U.S. have received their COVID shots and routine vaccinations resume, execs said. The CDC recommends people don’t receive other vaccines within 2 weeks of their COVID-19 shots.

Amid those struggles, it’s a good thing for Merck that its cancer stalwart Keytruda continued its ascent. The drug pulled in a whopping $3.9 billion during the quarter, up around 19% versus the same period last year.

RELATED: Gilead, Merck step in to help India’s drug manufacturers fight surging COVID-19 outbreak

Looking forward, while Merck says M&A isn’t off the table, one analyst figures there’s plenty to like in the company’s existing portfolio and pipeline.

“[W]e still believe there is a lot of value to be unlocked in [Merck’s] products as well as its pipeline,” Cantor Fitzgerald analysts wrote in a note to clients Thursday morning. Growth across oncology, vaccines, animal health and select hospital and specialty care products remain “underappreciated,” the analysts wrote.

Plus, the company snagged recent approvals for Keytruda in esophageal cancer, and for new med Verquvo in chronic heart failure.

All told, the company now forecasts between $51.8 billion to $53.8 billion in 2021 sales.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...